Orally bioavailable small molecule drug protects memory in Alzheimer's disease models

Neurobiology of Aging

Volumn 34, Issue 4, 2013, Pages 1116-1125

  O'Hare, Eugene ^a   Scopes, David I C ^b   Kim, Eun Mee ^c   Palmer, Philip ^a   Jones, Martyn ^d   Whyment, Andrew D ^d   Spanswick, David ^d,e   Amijee, Hozefa ^b   Nerou, Edmund ^b   McMahon, Bridgeen ^a   Treherne, J Mark ^b   Jeggo, Ross ^d  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b Senexis Limited   (United Kingdom)

^c UNIVERSITY OF ULSTER   (United Kingdom)

^d NEUROSOLUTIONS LTD   (United Kingdom)

^e UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

amyloid peptide; Alzheimer's disease; Biochemistry; Long term potentiation; Operant behavior; Therapeutics

Indexed keywords

2 FLUORO 5 [5 (3 MORPHOLIN 4 YLPHENOXY) PYRIMIDIN 2 YLAMINO]BENZONITRILE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; MONOMER; OLIGOMER; PYRIMIDINE DERIVATIVE; RECOMBINANT PROTEIN; SEN 1500; THIOFLAVINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROTECTION; CYTOTOXICITY; DETERIORATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; EMBRYO; ENZYME INHIBITION; IN VITRO STUDY; IN VIVO STUDY; LONG TERM POTENTIATION; MALE; MAXIMUM PLASMA CONCENTRATION; MEMORY; MOUSE; NERVE CELL; NERVE CELL PLASTICITY; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ALZHEIMER DISEASE; ANIMALS; MALE; MEMORY; MEMORY DISORDERS; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; SYNAPTIC TRANSMISSION;

EID: 84872294176     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2012.10.016     Document Type: Article

References (49)

1. Aisen P.S., Gauthier S., Ferris S.H., Saumier D., Haine D., Garceau D., Duong A., Suhy J., Oh J., Lau W.C., Sampalis J. Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study). Arch. Med. Sci. 2011, 7:102-111.
2. Amijee H., Scopes D.I. The quest for small molecules as amyloid inhibiting therapies for Alzheimer's disease. J. Alzheimers Dis. 2009, 17:33-47.
3. Areosa S.A., Sherriff F., McShane R. Memantine for dementia. Cochrane Database Syst. Rev. 2005, 20:CD003154.
4. 1-42-mediated synapse damage in vitro. J. Mol. Neurodegen 2008, 3:1-9.
5. Bilikiewicz A., Gaus W. Colostrinin (a naturally occurring, proline-rich, polypeptide mixture) in the treatment of Alzheimer's disease. J. Alzheimers Dis. 2004, 6:17-26.
6. Cleary J.P., Walsh D.M., Hofmeister J.J., Shankar G.M., Kuskowski M.A., Selkoe D.J., Ashe K.H. Natural oligomers of the amyloid-β protein specifically disrupt cognitive function. Nat. Neurosci. 2005, 8:79-84.
7. Danysz W., Parsons C.G. The NMDA receptor antagonist Memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int. J. Geriatr. Psychiatry 2003, 18:S23-S32.
8. Farlow M.R. Do cholinesterase inhibitors slow progression of Alzheimer's disease?. Int. J. Clin. Pract. Suppl. 2002, 127:37-44.
9. Froud K.E., Wardhaugh T., Banks D., Saffrey M.J., Stewart M.G. Colostrinin alleviates amyloid-beta induced toxicity in rat primary hippocampal cultures. J. Alzheimers Dis. 2010, 20:423-426.
10. Gervais F., Paquette J., Morissette C., Krzywowski P., Yu M., Azzi M., Lacombe D., Kong X., Aman A., Laurin J., Szarek W.A., Tremblay P. Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol. Aging 2007, 28:537-547.
11. Glabe C. Structural classification of toxic amyloid oligomers. J. Biol. Chem. 2008, 283:29639-29643.
12. Haass C., Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell. Biol. 2007, 8:101-112.
13. Janusz M., Woszczyna M., Lisowski M., Kubis A., Macala J., Gotszalk T., Lisowski J. Ovine colostrums nanopeptide affects amyloid beta aggregation. FEBS Lett. 2009, 583:190-196.
14. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., Glabe C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003, 300:486-489.
15. Lipton S.A. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like Memantine in the treatment of acute and chronic neurological insults. NeuroRx 2004, 1:101-110.
16. McLaurin J., Golomb R., Jurewicz A., Antel J.P., Fraser P.E. Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit abeta-induced toxicity. J. Biol. Chem. 2000, 275:18495-18502.
17. McLaurin J., Kierstead M.E., Brown M.E., Hawkes C.A., Lambermon M.H., Phinney A.L., Darabie A.A., Cousins J.E., French J.E., Lan M.F., Chen F., Wong S.S., Mount H.T., Fraser P.E., Westaway D., St George-Hyslop P. Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat. Med. 2006, 12:801-808.
18. Nakagami Y., Nishimura S., Murasugi T., Kenko I., Meguro M., Marumoto S., Kogen H., Koyama K., Oda T. A novel β-sheet breaker, RS-0406, reverses amyloid β-induced cytotoxicity and impairment of long-term potentiation in vitro. Br. J. Pharmacol 2002, 137:676-682.
19. Nitz M., Fenili D., Darabie A.A., Wu L., Cousins J.E., McLaurin J. Modulation of amyloid-beta aggregation and toxicity by inosose stereoisomers. FEBS J. 2008, 275:1663-1674.
20. O'Hare E., Scopes D.I., Treherne J.M., Norwood K., Spanswick D., Kim E.-M. RS-0406 arrests amyloid-beta oligomer-induced behavioural deterioration in vivo. Behav. Brain Res. 2010, 210:32-37.
21. Ondrejcak T., Klyubin I., Hu N.W., Barry A.E., Cullen W.K., Rowan M.J. Alzheimer's disease amyloid beta-protein and synaptic function. Neuromolecular Med. 2010, 12:13-26.
22. Parsons C.G., Danysz W., Quack G. Memantine is a clinically well tolerated NMDA receptor antagonist - a review of preclinical data. Neuropharmacology 1999, 38:735-767.
23. Parsons C.G., Gilling K. Memantine as an example of a fast, open channel N-methyl-D-aspartate receptor blocker. Methods Mol. Biol. 2007, 403:15-36.
24. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1998, Academic Press, New York.
25. Podlisny M.B., Ostaszewski B.L., Squazzo S.L., Koo E.H., Rydell R.E., Teplow D.B., Selkoe D.J. Aggregation of secreted amyloid beta protein into sodium dodecyl sulphare-stable oligomers in cell culture. J. Biol. Chem. 1995, 270:9564-9570.
26. Podlisny M.B., Walsh D.M., Amorante P., Ostaszewski B.L., Stimson E.R., Maggio J.E., Teplow D.B., Selkoe D.J. Oligomerization of endogenous and synthetic amyloid beta protein at nanomolar levels in cell culture and stabilization of monomer by Congo red. Biochemistry 1998, 37:3602-3611.
27. Poling A., Morgan-Paisley K., Panos J.J., Kim E.-M., O'Hare E., Cleary J.P., Lesne S., Ashe K.H., Porritt M., Baker L.E. Oligomers of the amyloid-beta protein disrupt working memory: confirmation with two behavioural procedures. Behav. Brain Res. 2008, 193:230-234.
28. Popik P., Bobula B., Janusz M., Lisowski J., Vetulani J. Colostrinin, a polypeptide isolated from early milk, facilitates learning and memory in rats. Pharmacol. Biochem. Behav. 1999, 64:183-189.
29. Raschetti R., Albanese E., Vanacore N., Magginin M. Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS Med. 2007, 4:e338.
30. Reed M.N., Hofmeister J.J., Jungbauer L., Welzel A.T., Yu C., Sherman M.A., Lysne S., LaDu M.J., Walsh D.M., Ashe K.H., Cleary J.P. Cognitive effects of cell-derived and synthetically derived Aβ oligomers. Neurobiol. Aging 2011, 32:1784-1794.
31. Reisberg B., Doody R., Stoffler A., Schmitt F., Ferris S., Mobius H.J. Memantine in moderate-to-severe Alzheimer's disease. N. Engl. J. Med. 2003, 348:1333-1341.
32. Rishton G.M. Aggregator compounds confound amyloid fibrillization assay. Nature Chem. Biol. 2008, 4:159-160.
33. Schneider L.S., Dagermans K.S., Higgins J.P., McShane R. Lack of evidence for the efficacy of Memantine in mild Alzheimer's disease. Arch. Neurol. 2011, 68:991-998.
34. Scopes D.I.C., O'Hare E., Jeggo R., Whyment A.D., Spanswick D., Kim E.-M., Gannon J., Amijee H., Treherne J.M. Aβ oligomer toxicity inhibitor protects memory in models of synaptic toxicity. Br. J. Pharmacol. 2012, 167:383-392.
35. Shah S., Reichman W.E. Treatment of Alzheimer's disease across the spectrum of severity. Clin. Interv. Aging 2006, 1:131-142.
36. Shankar G.M., Mehta T.H., Garcia-Munoz A., Shepardson N.E., Smith I., Brett F.M., Farrell M.A., Rowan M.J., Lemere C.A., Regan C.M., Walsh D.M., Sabatini B.L., Selkoe D.J. Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 2008, 14:837-842.
37. Shankar G.M., Welzel A.T., McDonald J.M., Selkoe D.M., Walsh D.M. Isolation of low-n amyloid β-protein oligomers from cultured cells, CSF and brain. Methods Mol. Biol. 2011, 670:33-44.
38. Shearman M.S., Hawtin S.R., Tailor V.J. The intracellular component of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction is specifically inhibited by beta-amyloid peptides. J. Neurochem. 1995, 65:218-227.
39. Sun Y., Zhang G., Hawkes C.A., Shaw J.E., McLaurin J., Nitz M. Synthesis of scyllo-inositol derivatives and their effects on amyloid beta peptide aggregation. Bioorg. Med. Chem. 2008, 16:7177-7184.
40. Tanzi R.E., Moir R.D., Wagner S.L. Clearance of Alzheimer's Abeta peptide: the many roads to perdition. Neuron 2004, 43:605-608.
41. Tariot P.N., Farlow M.R., Grossberg G.T., Graham S.M., McDonald S., Gergel I. Memantine treatment in patients with moderate to severe Alzheimer's disease already receiving donepezil: a randomized controlled trial. JAMA 2004, 291:317-324.
42. Townsend M., Cleary J.P., Mehta T., Hofmeister J., Lesne S., O'Hare E., Walsh D.M., Selkoe D.K. Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers. Ann. Neurol. 2006, 60:668-676.
43. Traykov L., Baudic S., Raoux N., Latour F., Rieu D., Smagghe A., Rigaud A.S. Patterns of memory impairment and perseverative behaviour discriminate early Alzheimer's disease from subcortical vascular dementia. J. Neurol. Sci. 2005, 229:75-79.
44. Verdile G., Fuller S., Atwood C.S., Laws S.M., Gandy S.E., Martins R.N. The role of beta amyloid in Alzheimer's disease: still a cause of everything or the only one who got caught?. Pharmacol. Res. 2004, 50:397-409.
45. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416:535-539.
46. Walsh D.M., Selkoe D.J. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004, 44:181-193.
47. Walsh D.M., Selkoe D.J. Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept. Lett. 2004, 11:213-228.
48. Walsh D.M., Townsend M., Podlisny M.B., Shankar G.M., Fadeeva J.V., El-Agnaf O., Hartley D.M., Selkoe D.J. Certain inhibitors of synthetic amyloid β-peptide (Aβ) fibrillogenesis block oligomerization of natural Aβ and thereby rescue long-term potentiation. J. Neurosci. 2005, 25:2455-2462.
49. Walsh D.M., Tseng B.P., Rydell R.E., Podlisny M.B., Selkoe D.J. The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry 2000, 39:10832-10839.